Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hematol. Nov 12, 2018; 7(1): 1-3
Published online Nov 12, 2018. doi: 10.5315/wjh.v7.i1.1
miRNA and platelet genetic machinery
Pedro C Redondo
Pedro C Redondo, Department of Physiology, Institute of Molecular Pathology Biomarkers, University of Extremadura, Caceres 10003, Spain
Author contributions: Redondo PC has written the manuscript.
Conflict-of-interest statement: Redondo PC declares no conflict of interest related to this publication.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author to: Pedro C Redondo, PhD, Academic Research, Professor, Department of Physiology, Institute of Molecular Pathology Biomarkers, University of Extremadura, Plaza de Caldereros, s/n., Caceres 10003, Spain. pcr@unex.es
Telephone: +34-927-257106 Fax: +34-927-257110
Received: June 29, 2018
Peer-review started: July 2, 2018
First decision: August 9, 2018
Revised: September 14, 2018
Accepted: November 2, 2018
Article in press: November 2, 2018
Published online: November 12, 2018
Core Tip

Core tip: miRNAs have been recently identified as a mechanism for regulating protein content in several cell types including platelets. In fact, certain miRNAs have been recently associated with some platelet-related pathologies. Moreover, changes in the miRNAs expression profiles have been evidenced in platelet activated by certain agonists. So, future researches will be needed to provide more information regarding platelet miRNAs in order to be used as an alternative therapy to the nowadays antiplatelet drugs.